Table 2.

Resistance to indomethacin-induced fetal DA closure and neonatal mortality results from the deficiency of COX-2

Offspring genotype	Fetal DA closure,* % incidence	Neonatal survival,† % incidence
COX-1(+/+)/COX-2(+/+)	100 (6/6)	0 (0/7)
COX-1(+/−)/COX-2(+/+)	100 (5/5)	0 (0/5)
COX-1(−/−)/COX-2(+/+)	100 (6/6)	0 (0/8)
COX-1(+/+)/COX-2(+/−)	100 (6/6)	0 (0/6)
COX-1(+/−)/COX-2(+/−)	100 (6/6)	0 (0/8)
COX-1(−/−)/COX-2(+/−)	100 (8/8)	0 (0/14)
COX-1(+/+)/COX-2(−/−)	0 (0/6)	100 (5/5)
COX-1(+/−)/COX-2(−/−)	0 (0/6)	100 (7/7)
COX-1(−/−)/COX-2(−/−)	0 (0/6)	100 (12/12)

^*Indomethacin-induced fetal DA closure was determined on gestation day 18.5 after maternal indomethacin administration 4 h prior to Cesarean delivery. In parentheses are number closed/number analyzed. 

^† Neonatal survival after maternal indomethacin administration was determined after Cesarean delivery on gestation day 19.5. The surviving pups were sacrificed 5 h after birth. In parentheses are number alive/number born.